<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473251</url>
  </required_header>
  <id_info>
    <org_study_id>VARI 2011 002</org_study_id>
    <nct_id>NCT01473251</nct_id>
  </id_info>
  <brief_title>Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration</brief_title>
  <official_title>Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitreo-Retinal Associates, Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vitreo-Retinal Associates, Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure biomarkers in the vitreous of patients undergoing
      Lucentis or avastin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of collected vitreous samples to identify biomarkers.</measure>
    <time_frame>End of study</time_frame>
    <description>Analysis of collected vitreous samples in regards to identification of biomarkers that are prognostic for response to anti-angiogenic treatment of retinopathy, and the exploration of a more effective dosing regiment for intravitreal injections of Lucentis/Avastin for exudative macular degeneration and Avastin for diabetic macular edema.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Exudative Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Avastin for Diabetic Macular Edema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25 mg avastin monthly for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin for Exudative Macular Degeneration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25 mg Avastin monthly for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis for Exudative Macular Degeneration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg Lucentis monthly for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>1.25 mg monthly for 4 months</description>
    <arm_group_label>Avastin for Diabetic Macular Edema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>1.25 mg monthly for 4 months</description>
    <arm_group_label>Avastin for Exudative Macular Degeneration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.5 mg monthly for 4 months</description>
    <arm_group_label>Lucentis for Exudative Macular Degeneration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 to 85 with diabetes and hemoglobin A1C &lt;/= 10, or exudative
             macular degeneration.

          -  Diabetic macular edema with average retinal thickness central subfield &gt;/= 290um.

        Exclusion Criteria:

          -  Macular atrophy/fibrosis.

          -  Ocular anti-VEGF treatment within 3 months.

          -  Treatment with topical or oral carbonic-anhydrase inhibitor within one month

          -  Laser photocoagulation within 3 months (diabetic cohort)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis C. Glazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitreo Retinal Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

